Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

NCT07664735 is registered in ClinicalTrials.gov with Outpace Bio, Inc. as lead sponsor.

NCT NCT07664735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07664735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.
Lead sponsor
Outpace Bio, Inc.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
September 30, 2030
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endometrial cancer, endometrial cancer, endometrial cancer recurrent, endometrial cancers, ovarian cancer, ovarian cancer recurrent, platinum resistant ovarian cancer